RxDoctor Payments Data

Moiuri Siddique

Urogynecology and Reconstructive Pelvic Surgery · Washington, DCNPI 1174919542

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,622 of the $4,364 with a category attached, or 60.1%. Axonics, Inc. accounts for 70.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $3,177 and has fallen 95.8% since, to $134 in 2025.

$4,364in general payments, 2019–2025

Across 54 payments — averaging $80.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$3K
  • Boston Scientific$333
  • Sumitomo Pharma America, Inc.$324
  • Medtronic$316
  • Applied Medical Resources Corporation$92
  • Merck$87
  • plus $149 from 6 others

What the payments were for

  • Travel & lodging$2,62260%
  • Food & beverage$1,74240%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$104,001
Medicare patients
191
Services billed
3,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron246$184,736
MyrbetriqMirabegron113$53,179
BotoxOnabotulinumtoxina16$9,486
Estradiol126$7,116
Mirabegron ErMirabegron12$3,746
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst76$1,021
NitrofurantoinNitrofurantoin Macrocrystal21$455
Trospium Chloride11$393
Cephalexin26$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$324$184,736246 claims
AbbVieBotox$60$9,48616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →